This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
ARID1A is required for response of ER+ breast cancer cells to tamoxifen and fulvestrant but not JQ1.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
March 2020
Volume 10, Issue 3
Volume 10, Issue 3
mSWI/SNF Component ARID1A Mediates Breast Cancer Treatment Response
Jump to section
Advertisement